Drug Trial Radar · NCT01904162
Effect of Age and Gender on the PK and Tolerability of Finafloxacin
Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Feb 2010
Primary completion
Feb 2010
Study completion Feb 2010
Sponsor
- Lead sponsor
- MerLion Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Previous clinical studies have indicated that finafloxacin is well-tolerated with few treatment-related adverse events. As a part of the clinical development of finafloxacin, other PK studies are required to determine the effect of other variables on the PK profile of finafloxacin. This study aims to determine the effect of age and gender on the pharmacokinetic profile of finafloxacin.
Conditions
- Pharmacokinetic and Tolerability of Finafloxacin
Interventions
400 mg finafloxacin (2 x 200 mg tablets)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- PharmacokineticTime frame: Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion (formerly MDS Pharmaservices)
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.